Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases

Documenti analoghi

• Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis
  di: Beyersdorf, Niklas, et al.
  Pubblicazione: (2005)
• Topological Requirements and Signaling Properties of T Cell–activating, Anti-CD28 Antibody Superagonists
  di: Lühder, Fred, et al.
  Pubblicazione: (2003)
• Self-Recognition Sensitizes Mouse and Human Regulatory T Cells to Low-Dose CD28 Superagonist Stimulation
  di: Langenhorst, Daniela, et al.
  Pubblicazione: (2018)
• CD28 co-stimulation in T-cell homeostasis: a recent perspective
  di: Beyersdorf, Niklas, et al.
  Pubblicazione: (2015)
• Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies
  di: Waibler, Zoe, et al.
  Pubblicazione: (2008)